Success Metrics

Completion Rate
0%(0/2)
Active Trials
6(67%)
Terminated
2(22%)

Phase Distribution

Ph phase_2
3
33%
Ph early_phase_1
1
11%
Ph phase_1
4
44%
Ph phase_3
1
11%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

6

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Terminated(3)

Detailed Status

Recruiting4
Active, not recruiting2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
6
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 23 (33.3%)
Phase 31 (11.1%)

Trials by Status

recruiting444%
withdrawn111%
active_not_recruiting222%
terminated222%

Recent Activity

6 active trials
Showing 5 of 9
active_not_recruitingphase_2

Azeliragon in MGMT Unmethylated Glioblastoma

NCT05986851
recruitingphase_1

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
recruitingphase_1

Concurrent Azeliragon With Craniospinal Irradiation

NCT06724926
recruitingearly_phase_1

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

NCT06831526
active_not_recruitingphase_2

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05986851Phase 2

Azeliragon in MGMT Unmethylated Glioblastoma

Active Not Recruiting
NCT05789589Phase 1

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Recruiting
NCT06724926Phase 1

Concurrent Azeliragon With Craniospinal Irradiation

Recruiting
NCT06831526Early Phase 1

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Recruiting
NCT05815485Phase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active Not Recruiting
NCT05773664Phase 1

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Withdrawn
NCT05766748Phase 1

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
NCT03980730Phase 2

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Terminated
NCT02080364Phase 3

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9